United States · Markets & Finance · The Motley Fool

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Published by The Motley Fool · United States 11 h ago

Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every other week or monthly (VK2735 also mimics the action of…

Read the full article on The Motley Fool Sign in to save

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

Cointelegraph

MetaMask exits Lido validators as it investigates security incident

Business Insider

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

OilPrice.com

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Share

Also worth reading

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.